#Teva Pharmaceuticals#Mexico#Company Report#Pharma#Medicine#Medicine

Teva Pharmaceuticals Mexico: revolutionizing the domestic medicine market

Since January 22, 2004, SICOR became Teva Pharmaceuticals affiliate. This acquisition brought together two top-level generic drug producers, combining T...

Admin
|Aug 30|magazine7 min read

Since January 22, 2004, SICOR became Teva Pharmaceutical’s affiliate. This acquisition brought together two top-level generic drug producers, combining Teva’s success at marketing oral ingested products, and Sicor’s leadership in injections. Also, the synergy between SICOR’s pharmaceuticals and biogeneric drug production increased the line of offered products for the company.

Click here to read the latest edition of Healthcare Global magazine!

Later, on January 26, 2006, acquisition of the IVAX Corporation was completed. IVAX conducts research, development, production and marketing for branded generics and veterinary products in the United States and abroad. IVAX brought along its strong presence in Latin America, Central and Eastern Europe, as well as other business endeavors in North America and the rest of Europe. Other product lines carried by IVAX include generic drugs for the respiratory system and products under development for oncology and CNS treatments. The affiliation of both companies brought a wider product portfolio, thus improving the cost-effect outcome both for generics as well as in branded products.

RELATED TOPIC: Brazil's pharmaceutical market value will approach $48 billion by 2020

In 2011, Teva bought Theramex, an European company run by Merck KGaA specialized in women’s health, which broadened Teva’s reach into gynecological products, which are available in more than 50 countries.

Teva’s activity in Japan increased after the acquisitions of Tayio and KOWA, in July and September 2011, respectively, reinforcing the company’s presence in the Asian country’s generics market.

RELATED TOPIC: Valeant Pharmaceuticals: Canada’s hottest stock after purchase of Addyi

Previously on May 2011, Cephalon was acquired along with its worldwide affiliates. The transaction brought a long-term strategy for Teva to grow its farmacopea both with branded products as well as with pharmaceutical specialties. A joint venture between ... Click here to read the rest of the article on Healthcare Global!

Let's connect!